# Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.

> **NCT07638852** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 58 (estimated)

## Conditions studied

- TNBC, Triple Negative Breast Cancer
- Brain Metastasases

## Interventions

- **RADIATION:** Radiation Therapy
- **DRUG:** Adebelimab
- **DRUG:** Bevacizumab
- **DRUG:** Cisplatin or carboplatin

## Key facts

- **NCT ID:** NCT07638852
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638852, "Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*